vs
Side-by-side financial comparison of Garden Stage Ltd (GSIW) and Prime Medicine, Inc. (PRME). Click either name above to swap in a different company.
Prime Medicine, Inc. is the larger business by last-quarter revenue ($838.0K vs $704.3K, roughly 1.2× Garden Stage Ltd). Garden Stage Ltd runs the higher net margin — -464.9% vs -5498.7%, a 5033.8% gap on every dollar of revenue. On growth, Garden Stage Ltd posted the faster year-over-year revenue change (0.0% vs -61.6%).
Virginia Stage Company (VSC) is a professional theater company located in Hampton Roads, Virginia. VSC presents locally produced plays for over 70,000 patrons a year both at the Wells Theatre in Norfolk, Virginia and throughout the community. A nonprofit theater, VSC has developed their "American Soil Series," a program that commissions plays of special regional interest, usually receiving their world premieres.
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
GSIW vs PRME — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $704.3K | $838.0K |
| Net Profit | $-3.3M | $-46.1M |
| Gross Margin | — | — |
| Operating Margin | — | -5800.5% |
| Net Margin | -464.9% | -5498.7% |
| Revenue YoY | 0.0% | -61.6% |
| Net Profit YoY | 0.0% | -9.0% |
| EPS (diluted) | — | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $838.0K | ||
| Q3 25 | $704.3K | $1.2M | ||
| Q2 25 | — | $1.1M | ||
| Q1 25 | — | $1.5M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | $1.2M | — | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $591.0K |
| Q4 25 | — | $-46.1M | ||
| Q3 25 | $-3.3M | $-50.6M | ||
| Q2 25 | — | $-52.6M | ||
| Q1 25 | — | $-51.9M | ||
| Q4 24 | — | $-42.3M | ||
| Q3 24 | $-3.3M | — | ||
| Q2 24 | — | $-55.3M | ||
| Q1 24 | — | $-45.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 77.4% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -5800.5% | ||
| Q3 25 | — | -4406.0% | ||
| Q2 25 | — | -4787.2% | ||
| Q1 25 | — | -3603.3% | ||
| Q4 24 | — | -2025.7% | ||
| Q3 24 | -277.9% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -8179.5% |
| Q4 25 | — | -5498.7% | ||
| Q3 25 | -464.9% | -4129.1% | ||
| Q2 25 | — | -4716.7% | ||
| Q1 25 | — | -3568.8% | ||
| Q4 24 | — | -1936.6% | ||
| Q3 24 | -277.5% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -7743.0% |
| Q4 25 | — | $-0.22 | ||
| Q3 25 | — | $-0.32 | ||
| Q2 25 | — | $-0.41 | ||
| Q1 25 | — | $-0.40 | ||
| Q4 24 | — | $-0.31 | ||
| Q3 24 | $0.21 | — | ||
| Q2 24 | — | $-0.46 | ||
| Q1 24 | — | $-0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $63.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $6.7M | $120.9M |
| Total Assets | $15.9M | $342.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $63.0M | ||
| Q3 25 | — | $71.4M | ||
| Q2 25 | — | $53.8M | ||
| Q1 25 | — | $91.9M | ||
| Q4 24 | — | $182.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $55.6M | ||
| Q1 24 | — | $94.2M |
| Q4 25 | — | $120.9M | ||
| Q3 25 | $6.7M | $161.8M | ||
| Q2 25 | — | $60.9M | ||
| Q1 25 | — | $106.9M | ||
| Q4 24 | — | $153.1M | ||
| Q3 24 | $6.9M | — | ||
| Q2 24 | — | $196.6M | ||
| Q1 24 | — | $243.8M |
| Q4 25 | — | $342.7M | ||
| Q3 25 | $15.9M | $385.0M | ||
| Q2 25 | — | $279.0M | ||
| Q1 25 | — | $328.2M | ||
| Q4 24 | — | $297.5M | ||
| Q3 24 | $15.6M | — | ||
| Q2 24 | — | $259.7M | ||
| Q1 24 | — | $311.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-809.6K | $-37.3M |
| Free Cash FlowOCF − Capex | — | $-37.5M |
| FCF MarginFCF / Revenue | — | -4480.4% |
| Capex IntensityCapex / Revenue | — | 34.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-167.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-37.3M | ||
| Q3 25 | $-809.6K | $-35.0M | ||
| Q2 25 | — | $-41.4M | ||
| Q1 25 | — | $-48.9M | ||
| Q4 24 | — | $16.2M | ||
| Q3 24 | $-809.6K | — | ||
| Q2 24 | — | $-45.5M | ||
| Q1 24 | — | $-67.7M |
| Q4 25 | — | $-37.5M | ||
| Q3 25 | — | $-35.3M | ||
| Q2 25 | — | $-43.0M | ||
| Q1 25 | — | $-51.3M | ||
| Q4 24 | — | $14.5M | ||
| Q3 24 | $-1.0M | — | ||
| Q2 24 | — | $-47.4M | ||
| Q1 24 | — | $-70.0M |
| Q4 25 | — | -4480.4% | ||
| Q3 25 | — | -2880.5% | ||
| Q2 25 | — | -3855.1% | ||
| Q1 25 | — | -3526.8% | ||
| Q4 24 | — | 662.1% | ||
| Q3 24 | -87.1% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -11849.6% |
| Q4 25 | — | 34.6% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | — | 141.0% | ||
| Q1 25 | — | 166.6% | ||
| Q4 24 | — | 82.0% | ||
| Q3 24 | 18.5% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 393.2% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
